ALACHUA,
Fla. and CHICAGO,
May 14,
2024 /PRNewswire/ -- Nanopharmaceutics, Inc.
(OTC:TGRP), a clinical-stage pharmaceutical development company,
announced the initiation of a Phase I clinical study with the
Robert H. Lurie Comprehensive Cancer Center of Northwestern University "A Phase 1 Adaptive Dose
Escalation With Dose Expansion Study of Triapine in Combination
With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma"
(ClinicalTrials.gov Identifier: NCT06410248). The primary objective
of this phase 1 study will be to determine the recommended phase 2
dose (RP2D) for Triapine® in combination with temozolomide (TMZ).
Secondary objectives include evaluation of the safety profile of
Triapine® in combination with temozolomide (TMZ), progression-free
survival (PFS), overall survival (OS), overall response rate (ORR)
per RANO criteria, and quality of life per FACT-Br. The study will
recruit 40-45 patients with an established diagnosis of recurrent
glioblastoma, and there will be an exploratory arm to investigate
drug delivery into brain tumor tissue and target engagement in a
cohort who are surgical candidates for re-resection of recurrent
glioblastoma. Funding for the study is provided by BrainUp.
Oral Triapine® has been shown to be safe, tolerable,
and convenient in multiple clinical studies. Ribonucleotide
Reductase (RNR) Regulatory Subunit 2 (RRM2) targeting with
Triapine® may overcome chemoresistance and improve the
clinical efficacy of TMZ therapy. Preliminary research from Dr.
Atique Ahmed's lab at Northwestern University has uncovered a critical
factor that helps glioblastoma, an aggressive brain cancer, resist
chemotherapy treatment.
About the Robert H. Lurie Comprehensive Cancer Center of
Northwestern University
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is a National Cancer
Institute-designated Comprehensive Cancer Center located on
Northwestern Memorial Hospital's downtown medical campus in the
Streeterville neighborhood of Chicago,
Illinois, United
States.
About BrainUp
BrainUp is a nonprofit founded by Dan & Meg Kresach of Frankfort, Illinois. They founded BrainUp
after their only child Olivia, was diagnosed 10 years ago with a
Glioblastoma at the age of 22 years old. She died on
April 19, 2014. The Kresachs formed
BrainUp to fund brain cancer research. They have an annual run/walk
to raise money for brain cancer research. They have funded over
1.2 million dollars supporting brain
cancer research and trials at Chicago healthcare institutions. BrainUp is
the financial supporter of Karan
Dixit, M.D. (PI) and Atique
Ahmed, Ph.D of Northwestern
University Chicago,
Illinois. To learn more about BrainUp, visit brainup.ngo
About Nanopharmaceutics, Inc.
Nanopharmaceutics, Inc. is a clinical-stage specialty
pharmaceutical company developing oral, topical, and injectable
products for cancer, central nervous system (CNS) disorders, and
infectious diseases. Leveraging its expertise in nanoparticle and
fine-particle formulations, which can specifically be used to
improve hard-to-deliver BCS category II and IV drugs,
Nanopharmaceutics is focused on formulation development aimed at
improving drug absorption and stability.
Contact:
Nanopharmaceutics, Inc. (OTC: TGRP)
James D. Talton, Ph.D.
President and Chief Executive Officer
386-401-6304
www.nanopharmaceutics.com
View original
content:https://www.prnewswire.com/news-releases/nanopharmaceutics-and-northwestern-university-announce-initiation-of-phase-i-adaptive-dose-escalation-clinical-study-with-dose-expansion-of-oral-triapine-in-combination-with-temozolomide-tmz-for-patients-with-recurrent-glioblas-302145367.html
SOURCE Nanopharmaceutics, Inc.